39 results
8-K
TRML
Tourmaline Bio Inc
14 Dec 23
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
8:27am
14, 2023, Tourmaline Bio, Inc. (the “Company”) announced that, upon recommendation by the Nominating and Corporate Governance Committee
8-K
EX-10.2
p5msu0u qvxz
27 Oct 23
Departure of Directors or Certain Officers
5:17pm
8-K
iu3hsqs9bll
27 Oct 23
Departure of Directors or Certain Officers
5:17pm
8-K
EX-10.7
39vs8a
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
80c5lsmrjxjj2v7
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
424B3
k1440oo51lvx yolz9s
15 Sep 23
Prospectus supplement
6:31am
S-4/A
couboee91m 17r1mye
25 Aug 23
Registration of securities issued in business combination transactions (amended)
4:34pm
S-4
q1nvydmkyl
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
425
astshbhjmn t2olil
22 Jun 23
Business combination disclosure
9:12am
8-K
EX-2.1
lrm5qyhd 2f
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am